
Serinus Biosciences
Serinus Biosciences is a YC Summer 2022 (S22) company. Based in New York, NY, USA. Team of 6.
About Serinus Biosciences
Summary
Serinus Biosciences builds an AI platform that designs combination cancer therapies to defeat treatment resistance. The platform draws on systems biology to map how cancer cells develop resistance and identify molecular combinations that block those escape routes. It replaces largely trial-and-error combination screening with a mechanistically grounded, explainable computational approach aimed at producing safer, faster-to-clinic regimens.
From the Y Combinator listing
Combinations therapy by rational design
Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.
Facts
- Healthcare / Healthcare -> Therapeutics
- New York, NY, USA
- 6
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works